



BSW Formulary Updates and Recent Decisions – October 2025

New additions to BSWformulary and Change in Traffic Light Status (TLS)

- **Ryaltris** – added with **GREEN** traffic light as a cost-effective alternative to Dymista for moderate to severe allergic rhinitis. Dymista moved to non-formulary, not to be prescribed for new patients.
- **Afqir (afibercept biosimilar)** – added with **RED** traffic light as first-line treatment for all licensed indications.
- **Ephedrine pre-filled syringe** – added with **RED** traffic light for use in anaesthetics as an alternative to ephedrine vials as a cost effective and safer alternative.

New and Updated Prescribing Guidelines and Shared Care Agreements

- **Denosumab prescribing guidance** – shared care agreement moved to prescribing guidance as it is included in the LCS and can now be initiated in primary care on written advice from rheumatology or care of the elderly teams (AMBER).
- **Antibiotic back up prescription guidance** – published for use within primary care. This leaflet gives information and prescribing advice.
- **Erectile Dysfunction guidance** – Updated first-line treatment option to include generic tadalafil as there is no SLS requirement now.
- **Rybelsus (oral semaglutide)** – guidance updated to include new products, providing information on equivalent doses and strengths.
- **COPD inhaler guidance** – updated following the NICE guidance update. Combination inhalers are the preferred choice. Trixeo added as a treatment option.
- **Asthma Guidance update** – Bibecfo added as a treatment option ahead of Luforbec as a better tolerated MDI and a cost-effective option.

Minor amendments to Netformulary

- Discontinuation of Exenatide long acting. MSN suggests switching to another GLP1.
- Bibecfo added to formulary as ingredients already listed.
- Acarizax moved to non-formulary as no specialist allergy clinics in BSW.
- Bimatoprost/timolol eye drop entries updated.

What the BSW ICB formulary team are currently working on

- Updating Entresto (sacubitril/valsartan) guidance
- Insulin formulary update
-
- Producing an amiodarone SCA

The BSW joint formulary remains under construction and is designed to be an evolving, dynamic resource. We are working to ensure the messages on GP prescribing systems and Optimise Profiles are in line with the joint formulary. If you discover information you believe to be inaccurate or misleading, or for further information, email bswicb.formulary@nhs.net